Pure Global

Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer - Trial NCT06228053

Access comprehensive clinical trial information for NCT06228053 through Pure Global AI's free database. This Phase 2 trial is sponsored by Syntrix Biosystems, Inc. and is currently Not yet recruiting. The study focuses on Metastatic Castration-resistant Prostate Cancer. Target enrollment is 53 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06228053
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06228053
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer, the SYNERGY-201 Trial

Study Focus

SX-682

Interventional

drug

Sponsor & Location

Syntrix Biosystems, Inc.

Los Angeles,San Francisco,Ann Arbor,Minneapolis,Durham,Madison, United States of America

Timeline & Enrollment

Phase 2

May 01, 2024

Jun 30, 2028

53 participants

Primary Outcome

Clinical Benefit

Summary

The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in
 men with metastatic castration resistant prostate cancer (mCRPC) who have failed abiraterone.

ICD-10 Classifications

Malignant neoplasm of prostate
Hyperplasia of prostate
Carcinoma in situ: Prostate
Special screening examination for neoplasm of prostate
Dysplasia of prostate

Data Source

ClinicalTrials.gov

NCT06228053

Non-Device Trial